CS
OVID icon

Credit Suisse’s Ovid Therapeutics OVID Stock Holding History

Credit Suisse’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-14,568
Closed -$33K – 4486
2020
Q4 		$33K Buy
+14,568
New +$67.9K ﹤0.01% 4281
2020
Q2 		– Sell
-11,746
Closed -$35K – 4095
2020
Q1 		$35K Sell
11,746
-260,418
-96% -$878K ﹤0.01% 3924
2019
Q4 		$1.13M Buy
+272,164
New +$859K ﹤0.01% 3031

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse's OVID Position: Q1 2021 in Review

Credit Suisse sold out of Ovid Therapeutics (OVID) in Q1 2021, closing a stake of 14,568 shares — an estimated $33K sold.

Credit Suisse first reported a position in OVID in Q4 2019 and held it in 3 quarters. The position peaked at $1.13M in Q4 2019. 88 funds tracked by Wall St. Rank hold OVID as of Q1 2021.

  • Credit Suisse reported no remaining Ovid Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Credit Suisse sold 14,568 Ovid Therapeutics shares in Q1 2021, an estimated $33K.
  • Credit Suisse first reported a position in Ovid Therapeutics in Q4 2019 and held it in 3 quarters.
  • Credit Suisse's Ovid Therapeutics position peaked at $1.13M in Q4 2019.
  • 88 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2021.

Based on Credit Suisse's 13F filing for Q1 2021, filed 14 May 2021.